Información del artículo
Resumen
Etravirina (ETR) es un inhibidor de la transcriptasa inversa no análogo de nucleósidos (ITINAN), con potente y amplia actividad in vitro frente al virus de la inmunodeficiencia humana 1 y a virus con resistencias a ITINAN, lo que permite el uso secuencial de esta familia. La potencia, eficacia y seguridad están demostradas en pacientes multitratados, pero se dispone de pocos datos en primeras líneas de tratamiento antirretroviral (TAR), sin estar definido su papel en fases iniciales. La presencia de resistencias a ITINAN primarias y adquiridas durante la primera línea de tratamiento es cada vez más frecuente. Gracias a su barrera genética y eficacia, ETR puede formar parte de un segundo régimen de TAR en pacientes que han fallado en un primer régimen. En fases iniciales, los efectos adversos siguen siendo el motivo principal por el que se modifica el TAR. ETR se ha mostrado segura y con buena tolerabilidad. No presenta efectos adversos en el sistema nervioso central y tiene un buen perfil hepático, lipídico y gastrointestinal. El efecto adverso más frecuente es el exantema, efecto adverso común al resto de ITINAN. Su buen perfil de tolerabilidad lo convierte en un fármaco que se debe considerar en la configuración de un nuevo tratamiento en cambios por tolerabilidad. Las características de ETR, posibilidad de administración 1 vez al día, posibilidad de administrar disuelta en agua y no interacción con metadona, hacen que sea un fármaco especialmente atractivo en primeras líneas de tratamiento y en pacientes a los que se les ha atribuido mala adherencia, como son los usuarios de drogas por vía parenteral en tratamiento con metadona.
Palabras clave:
VIH
Etravirina
Resistencias VIH
Tolerabilidad
Metadona
Abstract
Etravirine (ETR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with a potent and broad in vitro spectrum of activity against HIV-1 and viruses with NNRTI resistances, allowing sequential use of drugs of this family. The potency, efficacy and safety of etravirine have been demonstrated in multi-treated patients, but few data are available on first-line antiretroviral therapy (ART) and the role of this drug in initial treatment phases has not been defined. The presence of primary NNRTI resistances and those acquired during first-line therapy is increasingly frequent. Due to its genetic barrier and efficacy, ETR can form part of a second-line ART regimen in patients with failure to a first-line regimen. In the initial phases, adverse effects continue to be the main reason for modifying ART. ETR has demonstrated safety and tolerability, with no central nervous system adverse effects and a good liver, lipid and gastrointestinal safety profile. As with the other NNRTIs, the most common adverse effect is rash. Because of ETR good tolerability profile, this drug can be considered when a new treatment is required due to adverse effects. Because of the characteristics of ETR the possibility of once-daily administration and dissolution in water, as well as the absence of drug-drug interactions with methadone this drug is especially attractive as a firstline therapy and in patients with poor adherence, such as intravenous drug users receiving methadone treatment.
Keywords:
HIV
Etravirine
Resistances HIV
Tolerability
Methadone
El Texto completo está disponible en PDF
Bibliografía
[1.]
F.J. Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
N Engl J Med, 338 (1998), pp. 853-860
[2.]
A. Mocroft, B. Ledergerber, C. Katlama, O. Kirk, P. Reiss, A. D’Arminio Monforte, et al.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Lancet, 362 (2003), pp. 22-29
[3.]
R.D. Moore, J.C. Keruly, K.A. Gebo, G.M. Lucas.
An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.
J Acquir Immune Defic Syndr, 39 (2005), pp. 195-198
[4.]
S. Deeks, The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the Ie DEA.
Trends in second virologic failure and predictors of subsequent mortality among ART-experienced patients: North American experience.
Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections,
[5.]
K. Andries, H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, et al.
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against non-nucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Antimicrob Agents Chemother, 48 (2004), pp. 4680-4686
[6.]
J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, DUET-1 study group, et al.
Efficacy and safety of TMC125 (etravirine) in treatmentexperienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, doubleblind, placebo-controlled trial.
Lancet, 370 (2007), pp. 29-38
[7.]
A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, et al.
DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatmentexperienced HIV-1- infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial.
Lancet, 370 (2007), pp. 39-48
[8.]
US Department of Health and Human Services (DHHS) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [consultado 2-7- 2008]. Disponible en: http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
[9.]
Recomendaciones de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana [consultado 17-7-2009] Disponible en: http://www.gesida.seimc.org
[10.]
A. Shet, L. Berry, H. Mohri, S. Mehandru, C. Chung, A. Kim, et al.
Tracking the prevalence of transmitted antirretroviral drug-resistant HIV-1: a decade of experience.
J Acquir Immune Defic Syndr, 41 (2006), pp. 439-446
[11.]
W. Wheeler, K. Mahle, U. Bodnar, D. Pienaizek, R. Kline, I. Hall, VS Variant, Atypical and Resistant HIV Surveillance (VARHS) Group, et al.
Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006.
Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections,
[12.]
C. De Mendoza, C. Rodríguez, J. Colomina, C. Tuset, F. García, J.M. Eiros, et al.
Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain.
Clin Infect Dis, 41 (2005), pp. 1350-1354
[13.]
SPREAD Programme.
Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
AIDS, 22 (2008), pp. 625-635
[14.]
Llenas-García J, Fiorante S, Julia Villar J, Maseda D, Delgado V, Hernando A, et al. Elevada frecuencia de resistencias primarias en pacientes inmigrantes con infección por el VIH en una unidad especializada en Madrid Programa de XIII Reunión de la SEIMC. Sevilla. Junio 2009. Resumen 142.
[15.]
V.A. Johnson, F. Brun-Vezinet, B. Clotet, H.F. Gunthard, D.R. Kuritzkes, D. Pillay, et al.
Update of the drug resistance mutations in HIV-1: fall 2006.
Top HIV Med, 14 (2006), pp. 125-130
[16.]
D.R. Kuritzkes, C.M. Lalama, H.J. Ribaudo, M. Marcial, W.A. Meyer 3rd., C. Shikuma, et al.
Preexisting resistance to nonnucleoside reverse- transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
J Infect Dis, 197 (2008), pp. 867-870
[17.]
R. Gupta, A. Hill, A.W. Sawyer, D. Pillay.
Emergence of drug resistance in HIV type-1- infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.
Clin Infect Dis, 47 (2008), pp. 712-722
[18.]
C. Delaugerre, R. Rohban, A. Simon, M. Mouroux, C. Tricot, R. Agher, et al.
Resistance profile and 21. Hang JQ, cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen.
J Med Virol, 65 (2001), pp. 445-448
[19.]
J. Vingerhoets, B. Clotet, M. Peeters, G. Picchio, L. Tambuyzer, K. Cao Van, et al.
Impact of Baseline NNRTI Mutations on the Virological Response to TMC125 (Etravirine; ETR) in the DUET-1 and DUET-2 Phase III Clinical Trials.
Program and abstracts of the 11th European AIDS Conference,
[20.]
A. Marcelin, P. Flandre, D. Descamps, L. Morand-Joubert, C. Charpentier, J. Izopet, The ANRS AC11 resistance group.
Factors associated with early virological response to etravirina in NNRTI experienced HIV-infected patients.
CROI, (2009),
[21.]
A. Mills, P. Cahn, J. Molina, S. Nijs, J. Vingerhoets, J. Witek.
Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96- week results.
Program and abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention,
[22.]
A. Holguín, M. Mulder, G. Yebra, M. López, V. Soriano.
Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native spaniards and immigrants in Spain.
Current HIV Research, 6 (2008), pp. 327-334
[23.]
Humphreys EH, Hernández LB, Rutherford GW. Antiretroviral regimens for patients with HIV who fail fi rst-line antiretroviral therapy (Cochrane Review) [consultado 27-7-2009]. Disponible en: http://www.thecochranelibrary.com
[24.]
N. Gianotti, S. Tiberi, S. Menzo, A. Danise, E. Boeri, L. Galli, et al.
HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy.
J Med Virol, 80 (2008), pp. 201-208
[25.]
M. Ait-Khaled, C. Stone, G. Amphlett, B. Clotet, S. Staszewski, C. Katlama, et al.
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
AIDS, 16 (2002), pp. 1686-1689
[26.]
B. Gruzdev, A. Rakhmanova, E. Doubovskaya, A. Yakovlev, M. Peeters, A. Rinehart, et al.
A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
AIDS, 17 (2003), pp. 2487-2494
[27.]
B.G. Gazzard, A.L. Pozniak, W. Rosenbaum, G.P. Yeni, S. Staszewski, K. Arasteh, et al.
An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 Infection days in HIV-1 infected individuals with NNRTI resistance. HIV-1 infected.
AIDS, 17 (2003), pp. F49-F54
[28.]
C. Cohen, C. Steinhart, D. Ward, P. Ruane, J. Vingerhoets, M. Peeters, et al.
Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study results of TMC125-C223.
Program and abstracts of the 16th tolerability International AIDS Conference,
[29.]
C. Katlama, J.M. Gatell, J.M. Molina, M. Peeters, J. Vingerhoets, B. Woodfall.
Pooled 24- week results of DUET-1 and -2: efficacy of TMC125 in treatmentexperienced HIV- 1-Infected patients.
Program and abstracts of the 11th European AIDS Conference,
[30.]
G. Di Perri, J. Madruga, K. Sathasivam, M. Peeters, J. Vingerhoets, C. Corbett, et al.
The impact of background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and DUET-2.
Program and abstracts of the XVIIth International AIDS Conference,
[31.]
Cordova E, Mingrone H, Porteiro N, Loiza E. Predicted susceptibility of etravirina in HIV patients experiencing virological failure secondary to nonnucleoside reverse transcriptase inhibitor resistance. Program and abstracts of the IAS. Cape Town, South Africa. 2009. Abstract MOPEB071.
[32.]
J.V. Madruga, D. Berger, M. McMurchie, F. Suter, D. Banhegyi, K. Ruxrungtham, et al.
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV infected patients in TITAN: a randomized controlled phase III trial.
Lancet, 370 (2007), pp. 49-58
[33.]
Eron J, Hicks C, Naggie S. Consequences of failure: outcomes and options after failure of the initial antiretroviral regimen. Clinical Care Options HIV [consultado 22-5-2009]. Disponible en: http://www.clinicaloptions.com/hiv.aspx
[34.]
J. Fellay, K. Boubaker, B. Ledergerber, E. Bernasconi, H. Furrer, M. Battegay, et al.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.
Lancet, 358 (2001), pp. 1322-1327
[35.]
E. Hart, H. Curtis, E. Wilkins, M. Johnson.
National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients.
HIV Med, 8 (2007), pp. 186-191
[36.]
F. Van Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, et al.
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised openlabel trial, the 2NN Study.
Lancet, 363 (2004), pp. 1253-1263
[37.]
R. Manfredi, L. Calza, F. Chiodo.
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
J Acquir Immune Defic Syndr, 35 (2004), pp. 492-502
[38.]
G. Di Perri, P.M. Girard, N. Clumeck, M. Peeters, M. Janssens, G. De Smedt.
Pooled 24- Week Results of Duet-1 and -2: TMC125 (Etravirine; ETR) Safety and Tolerability in Treatment-Experienced, HIV-1-Infected Patients.
Program and abstracts of the 11th European AIDS Conference/EACS,
[39.]
T. Campbell, B. Grinsztejn, J. Hartikainen, S. Nijs, J. Witek.
Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials.
Program and abstracts of the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention,
[40.]
B. Clotet, C. Katlama, A. Lazzarin, K. Janssen, T. Kakuda.
5 De Smedt G. Safety and tolerability of etravirine in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results.
Program and abstracts of the 9th International Congress on Drug Therapy in HIV Infection,
[41.]
Ficha técnica efavirenz. Disponible en: www.agemed.es
[42.]
R.M. Gulick, H.J. Ribaudo, C.M. Shikuma, C. Lalama, B.R. Schackman, W.A. Meyer 3rd., AIDS Clinical Trials Group (ACTG) A5095 Study Team, et al.
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
JAMA, 296 (2006), pp. 769-781
[43.]
C.R. Fumaz, J.A. Muñoz-Moreno, J. Moltó, E. Negredo, M.J. Ferrer, G. Sirera, et al.
Longterm neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
J Acquir Immune Defic Syndr, 38 (2005), pp. 560-565
[44.]
E. Martínez, J.A. Arnaiz, D. Podzamczer, D. Dalmau, E. Ribera, P. Domingo, et al.
Threeyear follow-up of protease inhibitor-based regimen simplification in HIV-infected patients AIDS, 21 (2007), pp. 367-369
[45.]
L. Boly, V. Cafaro, T. Dyner.
Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz.
J Acquir Immune Defic Syndr, 42 (2006), pp. 514-515
[46.]
C. Katlama, T. Campbell, M. Schechter, M. Peeters, C. Bicer, R. Sinha, et al.
Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the Phase III DUET studies.
Program and abstracts of the XVIIth International AIDS Conference,
[47.]
M. Boffito, A. Jackson, M. Lamorde, D. Back, V. Watson, J. Taylor, et al.
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
J Acquir Immune Defic Syndr, (2009),
[48.]
S. Riddler, R. Haubrich, G. DiRienzo, L. Peeples, W. Powderly, K. Klingman, et al.
Class- Sparing Regimens for Initial Treatment of HIV-1 Infection.
N Engl J Med, 358 (2008), pp. 2095-2106
[49.]
Interacciones medicamentosas con fármacos antirretrovirales [consultado 17-8- 2009] Disponible en: www.interaccioneshiv.com
[50.]
J.G. Gerber, S.L. Rosenkranz, C.J. Fichtenbaum, J.M. Vega, A. Yang, B.L. Alston, AIDS Clinical Trials Group A5108 Team, et al.
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
J Acquir Immune Defic Syndr, 39 (2005), pp. 307-312
[51.]
D.R. Bangsberg.
Preventing HIV antiretroviral resistance through better monitoring of treatment adherence.
J Infect Dis, 197 (2008), pp. S272-S278
[52.]
M. Egger, M. May, G. Chene, A.N. Phillips, B. Ledergerber, F. Dabis, et al.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Lancet, 360 (2002), pp. 119-129
[53.]
F. Lert, M.D. Kazatchkine.
Antiretroviral HIV treatment and care for injecting drug users: an evidencebased overview.
Int J Drug Policy, 18 (2007), pp. 255-261
[54.]
E. Word, R. Hogg, V. Lima, T. Kerr, B. Yip, B. Marshall, et al.
Highly Active Antiretroviral Therapy and Survival in HIV-Infected Injection Drug Users.
JAMA, 300 (2008), pp. 550-554
[55.]
G. Lucas, A. Mullen, P. Weidle, S. Hader, M. McCaul, R. Moore.
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.
Clinical Infectious Diseases, 42 (2006), pp. 1628-1635
[56.]
M. Schöller-Gyüre, W. Brink, T. Kakuda, B. Woodfall, G. De Smedt, H. Vanaken, et al.
Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.
J Clin Pharmacol, 48 (2008), pp. 322-329
[57.]
M. Schöller-Gyüre, T. Kakuda, G. De Smedt, B. Woodfall, R. Lachaert, G. Beets, et al.
Pharmacokinetics of TMC125 in once- and twice-daily regimens in HIV-1-negative volunteers.
Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy,
[58.]
J. Lalezari, E. DeJesus, O. Osiyemi, P. Ruane, Z. Haigney, R. Ryan, et al.
Pharmacokinetics of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults.
Program and abstracts of the Ninth International Congress on Drug Therapy in HIV Infection (HIV9),
[59.]
M. Schöller-Gyüre, T. Kakuda, R. Van Solingen-Ristea, C. Berckmans, G. De Smedt, M. Peeters, et al.
Bioavailability of the 100 mg etravirine tablet dispersed in water and of the 25 mg pediatric tablet formulation.
Program and abstracts of the XVIIth International AIDS Conference,
Copyright © 2009. Elsevier España S.L.. Todos los derechos reservados
